002901 Double Medical Technology Inc.Watchlist
About Double Medical Technology Inc. Company
The company was founded in 2004 and is located in the beautiful Ludao - Xiamen. It is a comprehensive medical listed enterprise focusing on orthopedics, neurosurgery, and minimally invasive surgery. The company has successively passed professional certifications such as FDA, CE, ISO13485, GMP, etc., and the product quality has been unanimously recognized by domestic and foreign users. With “promoting a national brand and building a healthy life” as its mission, Dabo has woven the Chinese dream of a great revival of the Chinese nation's medical industry through its strong economic strength, senior R&D strength, scientific management system, and forward-looking marketing strategy. The company's main business is the production, development and sale of high-value medical consumables. Its main products include orthopedic trauma implant consumables, spinal implant consumables, joint implant consumables, sports medicine and neurosurgery implant consumables, minimally invasive surgical consumables, dental implant consumables, etc. The company's main products include orthopedic trauma implant consumables, spinal implant consumables, joint implant consumables, sports medicine and neurosurgery implant consumables, minimally invasive surgical consumables, dental implant consumables, etc. Corporate honors: Accredited by the National Enterprise Technology Center, 2016-2017 Fujian Province's Contract-abiding and Trustworthy Enterprise, 2018-2019 Xiamen Leading Key Private Enterprise, Fujian Youth Entrepreneurship Outstanding Achievement Award, etc.
Anxin Securities: At the bottom of the orthopedic collection policy, it is now recommended to focus on Weigao Orthopedics (688161.SH), etc.
Anxin Securities believes that orthopedics has reached the bottom of the policy, that there is a low probability that the policy will be further tightened or that prices will drop further in the future, and prices have basically stabilized.
Dabo Healthcare (002901): Trauma collection bid renewal rules gently focus on the company's marginal changes
Investment points Trauma collection and bid renewal rules are moderate, and the bid price of the product may increase: On September 18, the Beijing-Tianjin-Hebei Pharmaceutical Joint Procurement Platform issued the “Provincial Alliance Notice on Centralized Procurement of Orthopedic Trauma Medical Consumables”. The renewal rules are relatively moderate, and
Anxin Securities: Trauma collection renewal rules focus more gently on valuation repair opportunities for leading targets
It is recommended to focus on investment opportunities brought about by increased performance growth expectations and valuation repairs, which are the main targets of the orthopedic circuit.